METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA
Clinical trials for METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Matched conditions: METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
Radioactive drug targets tough prostate cancer
Disease control Recruiting nowThis study tests a radioactive drug called lutetium Lu 177 dotatate in men with advanced prostate cancer that has neuroendocrine features. The drug seeks out and kills cancer cells that have a specific protein on their surface. The goal is to see if it can shrink tumors. About 35…
Matched conditions: METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC